Rapport Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Rapport Therapeutics, Inc. (RAPP) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$765.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- Rapport Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$765.00K, a 4126.32% decline year-over-year.
- Rapport Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$1.05M, a 346.14% decline year-over-year.
- Rapport Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $401.00K.
- Rapport Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $221.00K, a 62.09% decline year-over-year.
- Rapport Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $1.07M.
- Rapport Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$526.00K, a 13250.00% decline from fiscal 2023.
- Rapport Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $4.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$765.00K 10-Q · filed 2026-08-05 | -$1.82M 10-Q · filed 2026-08-05 | -$1.42M derived: sum of 3 quarters · filed 2026-08-05 | -$1.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.05M 10-Q · filed 2026-05-07 | -$650.00K derived: sum of 2 quarters · filed 2026-05-07 | -$429.00K derived: sum of 3 quarters · filed 2026-05-07 | -$410.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $622.00K derived: sum of 2 quarters · filed 2026-03-10 | $641.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.07M 10-K · filed 2026-03-10 |
| 2025-09-30 | $221.00K 10-Q · filed 2025-11-06 | $240.00K derived: sum of 2 quarters · filed 2026-08-05 | $667.00K 10-Q · filed 2025-11-06 | -$255.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $19.00K 10-Q · filed 2026-08-05 | $446.00K 10-Q · filed 2026-08-05 | -$476.00K derived: sum of 3 quarters · filed 2026-08-05 | $107.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $427.00K 10-Q · filed 2026-05-07 | -$495.00K derived: sum of 2 quarters · filed 2026-05-07 | $88.00K derived: sum of 3 quarters · filed 2026-05-07 | $65.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$922.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$339.00K derived: sum of 2 quarters · filed 2026-03-10 | -$362.00K derived: sum of 3 quarters · filed 2026-03-10 | -$526.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $583.00K 10-Q · filed 2025-11-06 | $560.00K derived: sum of 2 quarters · filed 2025-11-06 | $396.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$23.00K 10-Q · filed 2025-08-07 | -$187.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$164.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $4.00K 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |